These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21205142)

  • 21. Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B.
    Wi CI; Kim WR; Gross JB; Stadheim LM; Poterucha JJ
    Gut Liver; 2016 Jul; 10(4):611-6. PubMed ID: 26190580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapeutic perspectives in HBV: when to stop NAs.
    Pérez-Cameo C; Pons M; Esteban R
    Liver Int; 2014 Feb; 34 Suppl 1():146-53. PubMed ID: 24373092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.
    Han M; Li Y; Wu W; Zhang Y; Yan W; Luo X; Ning Q
    Antiviral Res; 2017 Nov; 147():75-85. PubMed ID: 28988797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2011 Jan; 31 Suppl 1():90-4. PubMed ID: 21205144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hepatitis B: Is there still a role for interferon?
    Viganò M; Grossi G; Loglio A; Lampertico P
    Liver Int; 2018 Feb; 38 Suppl 1():79-83. PubMed ID: 29427498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a.
    Chen J; Wang Z; Guo Y; Peng J; Sun J; Ahmed CS; Zhou Y; Hou J
    Antiviral Res; 2009 Jan; 81(1):88-91. PubMed ID: 18948141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH; Flink HJ; Cakaloglu Y; Simon K; Trojan J; Tabak F; So TM; Feinman SV; Mach T; Akarca US; Schutten M; Tielemans W; van Vuuren AJ; Hansen BE; Janssen HL
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Protocol for the antiviral therapy of chronic hepatitis B].
    ;
    Orv Hetil; 2008 Dec; 149(49):2341-3. PubMed ID: 19042187
    [No Abstract]   [Full Text] [Related]  

  • 30. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic hepatitis B: current therapy].
    Buffet C
    Bull Acad Natl Med; 2008 Nov; 192(8):1625-37; discussion 1638-9. PubMed ID: 19445377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
    Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
    Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
    Asselah T; Marcellin P
    Clin Liver Dis; 2013 Aug; 17(3):445-50. PubMed ID: 23905815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Lampertico P
    J Hepatol; 2009 Apr; 50(4):644-7. PubMed ID: 19231017
    [No Abstract]   [Full Text] [Related]  

  • 36. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 37. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs in development for hepatitis B.
    Buti M; Esteban R
    Drugs; 2005; 65(11):1451-60. PubMed ID: 16033287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.
    Marcellin P; Sung J; Piratvisuth T
    Liver Int; 2010 May; 30(5):657-68. PubMed ID: 20158610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
    Marcellin P
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 2():S99-102. PubMed ID: 21095519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.